# US 2014/0193329 A1 · Anti-cd151 antibodies and their use in the treatment of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193329 A1 - Document ID: US20140193329A1 - Status: Published application - Kind: A1 - Application number: 14/049,617 - Filed: 2013-10-09 - Published: 2014-07-10 - Earliest claimed: 2008-04-11 - Assignees: Pierre Fabre Medicament - Applicants: Finnegan LLP - Inventors: Jean-François HAEUW - Web page: https://patentgrep.com/patent/US20140193329A1 ## CPC - C07K 16/30: from tumour cells - A61K 39/39558: {against tumor tissues, cells, antigens} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - A61K 2039/505: {comprising antibodies} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/565: Complementarity determining region [CDR] - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers. ## Claims ### Claim 1 An isolated antibody that is capable of binding to the CD151 protein and comprises: i) a light chain comprising CDR-L1, CDR-L2, and CDR-L3, wherein: CDR-L1 is chosen from SEQ ID No. 1 and SEQ ID No. 59; CDR-L2 is chosen from SEQ ID No. 2 and SEQ ID No. 60; CDR-L3 is SEQ ID No. 3; and ii) a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3, wherein CDR-H1 is chosen from SEQ ID No. 4 and SEQ ID No. 61; CDR-H2 is chosen from SEQ ID No. 5 and SEQ ID No. 62; CDR-H3 is chosen from SEQ ID No. 6 and SEQ ID No. 63; or a CD151-binding fragment of said antibody. ### Claim 2 (depends on 1) The isolated antibody according to claim 1, wherein the antibody comprises a light chain comprising SEQ ID No. 7 and a heavy chain comprising SEQ ID No. 8; or a CD151-binding fragment of said antibody. ### Claim 3 (depends on 1) The isolated antibody according to claim 1, wherein the antibody comprises a light chain comprising SEQ ID No. 101 and a heavy chain comprising SEQ ID No. 102; or a CD151-binding fragment of said antibody. ### Claim 4 (depends on 1) The isolated antibody according to claim 1, wherein the antibody comprises a light chain comprising SEQ ID No. 101 and a heavy chain comprising SEQ ID No. 103; or a CD151-binding fragment of said antibody. ### Claim 5 A murine hybridoma deposited at the CNCM (Collection Nationale de Cultures de Microorganismes), Institut Pasteur, Paris (France) on 22 Feb. 2008 under number I-3920. ### Claim 6 (depends on 1, 2, 3, 4, 5) A composition comprising an excipient or a pharmaceutically acceptable carrier, and: a) an antibody according to one of claims 1-4; b) an antibody produced by a hybridoma according to claim 5; or c) a CD151-binding fragment of an antibody as in a) or b). ### Claim 7 (depends on 6) The composition according to claim 6, further comprising as a combination product for simultaneous, separate, or time-staggered use, an antibody, a cytotoxic/cytostatic agent, a cell toxin, or a radioelement. ### Claim 8 (depends on 6) The composition of claim 6, wherein the antibody in a) is a chimeric antibody. ### Claim 9 (depends on 1, 2, 3, 4, 5) A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof an antibody according to one of claims 1-4, an antibody produced by the hybridoma according to claim 5, or a combination thereof. ### Claim 10 (depends on 9) The method according to claim 9, wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer. ### Claim 11 (depends on 5) An antibody secreted by the hybridoma according to claim 5. ### Claim 12 (depends on 1) The antibody of claim 1, wherein the antibody is a chimeric antibody. ### Claim 13 (depends on 1) The antibody of claim 1, wherein the antibody is a humanized antibody. ### Claim 14 (depends on 6) The composition according to claim 6, wherein the composition comprises: a) an antibody comprising a light chain comprising SEQ ID No. 7 and a heavy chain comprising SEQ ID No. 8; or b) CD151-binding fragment of said antibody. ### Claim 15 (depends on 11, 12) A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof an antibody according to any one of claims 11, 12, and 13. ### Claim 16 (depends on 2) A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof an antibody according to claim 2. ### Claim 17 (depends on 15) The method according to claim 15, wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer. ### Claim 18 (depends on 16) The method according to claim 16, wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer. ### Claim 19 (depends on 6) A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof a composition according claim 6. ### Claim 20 (depends on 19) The method according to claim 19, wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer. ### Claim 21 (depends on 7) A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof a composition according claim 7. ### Claim 22 (depends on 21) The method according to claim 21, wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer. ### Claim 23 (depends on 8) A method of treating a cancer comprising cells that express CD151, the method comprising administering to a subject in need thereof a composition according claim 8. ### Claim 24 (depends on 23) The method according to claim 23, wherein the cancer is chosen from prostate cancer, lung cancer, colon cancer, breast cancer, and pancreatic cancer. ### Claim 25 A recombinant antibody that is capable of binding to the CD151 protein and comprises: i) a light chain comprising CDR-L1, CDR-L2, and CDR-L3, wherein: CDR-L1 is chosen from SEQ ID No. 1 and SEQ ID No. 59; CDR-L2 is chosen from SEQ ID No. 2 and SEQ ID No. 60; CDR-L3 is SEQ ID No. 3; and ii) a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3, wherein CDR-H1 is chosen from SEQ ID No. 4 and SEQ ID No. 61; CDR-H2 is chosen from SEQ ID No. 5 and SEQ ID No. 62; CDR-H3 is chosen from SEQ ID No. 6 and SEQ ID No. 63; or a CD151-binding fragment of said antibody.